Breaking New Ground: Ozempic Shows Promise Against Dementia | CDC”>Alzheimer’s
A medication widely known for managing type 2 diabetes, Ozempic, may now hold significant promise for patients grappling with Alzheimer’s disease, according to recent scientific research. Semaglutide, the active ingredient in both Ozempic and Wegovy (for weight loss), could potentially slow down the progression of dementia and offer relief to patients with advanced Alzheimer’s.
Semaglutide’s potential impact on Alzheimer’s is not merely speculative; it’s grounded in rigorous studies. An ongoing study involving 3,680 Alzheimer’s patients in early stages is providing insight into its effectiveness. Previous studies have also been encouraging. Type 2 diabetes patients who take Ozempic appear to have a lower risk of developing Alzheimer’s and experience fewer symptoms when diagnosed.
A study conducted in the United States with an over one million diabetic participants revealed that those treated with semaglutide had a reduced risk, as high as 70%, of an Alzheimer’s diagnosis over three years. Diabetes, itself a recognized risk factor for dementia, affects brain metabolism. Medications in the GLP-1 class, including semaglutide, could represent a ray of hope for Alzheimer’s patients, as highlighted in a discussion at Alzheimer’s Disease International.
Dr. Jeff Cummings, a professor of brain science and health, emphasized the need to focus on more advanced patients, suggesting that drugs initially developed for milder cases could offer benefits across all stages of the disease. Donepezil, a widely used Alzheimer’s medication, serves as a testament to this. Initially tested for mild and moderate cases, it has proven effective in severe cases as well.
Semaglutide’s relative affordability compared to existing Alzheimer’s medications is another appealing factor. However, its use in elderly patients with dementia may carry risks, including reduced appetite and muscle loss, which can increase fall risk. Nevertheless, the potential of repurposing existing, safe drugs for Alzheimer’s treatment is a promising avenue. Approximately a third of medications currently in clinical trials for Alzheimer’s are already approved for other conditions.
Presently, two medications, lecanemab and donanemab, are approved for slowing Alzheimer’s progression in the UK, but they face financial barriers due to their high costs and questionable value. The potential of repurposing medications like semaglutide for Alzheimer’s—with lower risks and costs—is generating considerable interest as a potential game-changer in the fight against this devastating disease.
